Diligence memo · auto-generated · as of July 3, 2026

Plato BioPharma, Inc.

Plato BioPharma, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Plato BioPharma, Inc. operates in Pharma, based in WEST LAFAYETTE.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Plato BioPharma, Inc. has raised $3.6M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.0M on 2021-10-04.

Most recent recorded round closed around 2021-10-04.

Valuation (modeled)modeled

Provath models Plato BioPharma, Inc. at approximately $59M (range $2.3M–$331M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.04× the median modeled value of Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era. Within the normal band (104% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 137 months.

Last raise 4.7 yr ago; this sector typically re-raises about every 16 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 5.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 51% of Pharma peers (310 compared).

Modeled value ranks above 57% of those peers.

Closest niche peers: Zoo Pharma Dynamics Inc., Pharma-Labs Finance LLC, FSD Pharma Inc., Deepbiome Therapeutics, Inc., Pykus Therapeutics, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.